Breaking News
More () »

Alzheimer's drug that could slow disease approved by FDA

The drug is the first treatment that could potentially reduce the 'clinical decline' of those who have the disease.

WASHINGTON — The FDA approved aducanumab, a drug for treating Alzheimer's disease, Monday under its Accelerated Approval Program.

According to the Food and Drug Administration, the drug is the "first novel therapy" to be approved for Alzheimer's disease since 2003 and the first treatment directed at the underlying pathophysiology of the disease.

In other words, it would be the first drug approved and sold as a means to slow the progression of Alzheimer's, not just ease symptoms, according to The Washington Post.

The company filed for a Biologics License Application in July 2020. According to Biogen, the FDA initially was set to make its ruling in March; but in January the company said the FDA extended its review period for the drug until June. 

The accumulation of the protein in a person's brain is suspected to be a potential cause of Alzheimer's, according to the Alzheimer's Association. The "sticky" plaque is believed to damage communication between brain cells, eventually killing them. 

According to Biogen, aducanumab removes the amyloid-beta peptide-protein from an Alzheimer's patient's brain, which has shown in clinical trials to reduce the clinical decline of the disease.

However, the drug is not without controversy. 

In 2019, the company suspended two of its late-stage trials for the drug, citing the evidence in the trials was "unlikely to meet their primary endpoint." Additionally, two large trials run by Biogen appeared to have contradictory results, one showing the drug slowed patients' decline by 22 percent over 18 months while the other showed it was overall ineffective,  Bloomberg said.

And, an FDA advisory panel of medical experts has already rejected aducanumab, according to Bloomberg. 

Still, the treatment is "passionately" supported by patients and advocacy groups despite the advisory panel rejection, according to The Post.

The Washington Post, citing drug analysts, says aducanumab, an intravenous treatment, could cost up to $50,000-a-year per patient. And, the treatment doesn't cure the disease. 

RELATED: Their 12-year-old has childhood 'Alzheimer's.' $3 million is their only hope for saving him.

RELATED: Jack Hanna diagnosed with dementia, family says

What other people are reading right now:

►Breaking news and weather alerts: Get the free 10 Tampa Bay app

Stay In the Know! Sign up now for the Brightside Blend Newsletter

Before You Leave, Check This Out